National Cancer Institute; Amended Notice of Meeting, 28512 [07-2495]
Download as PDF
<![CDATA[
28512
Federal Register / Vol. 72, No. 97 / Monday, May 21, 2007 / Notices
pwalker on PROD1PC71 with NOTICES
Vaccine Against Escherichia Coli
0157 Infection, Composed of Detoxified
LPS Conjugated to Proteins
Description of Technology: This
invention is a conjugate vaccine to
prevent infection by E. coli 0157:H7,
particularly in young children under 5
years of age. E. coli 0157:H7 is an
emerging human pathogen which causes
a spectrum of illnesses with high
morbidity and mortality, ranging from
diarrhea to hemorrhagic colitis and
hemolytic-uremic syndrome (HUS).
Infection with E. coli 0157:H7 occurs as
a result of consumption of water,
vegetables, fruits or meat contaminated
by feces from infected animals, such as
cattle. The most recent large outbreak in
the U.S. was from contaminated bag
spinach. The conjugate is composed of
the O-specific polysaccharide isolated
from E. coli 0157, or other Shiga-toxin
producing bacteria, conjugated to carrier
proteins, such as non-toxic P.
aeruginosa exotoxin A or Shiga toxin 1.
A Phase I clinical trial, involving adult
humans, showed the vaccine is safe and
highly immunogenic. Adults, after one
injection containing 25 µg of antigen,
responded with high titers of
bactericidal antibodies. Similarly in a
phase II study, fifty 2-to-5- years old
children in U.S. were injected with the
conjugate vaccines. There were only
mild local adverse reactions. More than
90% of the children responded with
greater than 10 fold rise of E. coli O157
antibodies of bactericidal ability. Thus
the conjugates of the invention are
promising vaccines, especially for
children and the elderly, who are most
likely to suffer serious consequences
from infection.
Application: Prevention of E. coli
O157 infection.
Development Status: Clinical studies
have been performed and are described
in Konadu et al., J Infect Dis. 1998 Feb;
177(2):383–387 and Ahmed et al., J
Infect Dis. 2006 Feb; 193(2):515–526.
Inventors: Shousun C. Szu, Edward
Konadu, and John B. Robbins (NICHD).
Patent Status: U.S. Patent 6,858,211
issued 22 Feb 2005 (HHS Reference No.
E–158–1998/0–US–06); U.S. Patent
Application No. 10/987,428 filed 12
Nov 2004 (HHS Reference No. E–158–
1998/0–US–07); U.S. Patent Application
No. 11/015,436 filed 16 Dec 2004 (HHS
Reference No. E–158–1998/0–US–08).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Child Health
and Human Development, Laboratory of
VerDate Aug<31>2005
15:57 May 18, 2007
Jkt 211001
Developmental and Molecular
Immunity, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize Vaccine for E. coli O157
for Children and Adults. Please contact
John D. Hewes, Ph.D., at 301–435–3121
or hewesj@mail.nih.gov for more
information.
Dated: May 11, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–9656 Filed 5–18–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Advisory Board, June 14, 2007, 2 p.m.
to June 15, 2007, 12 p.m., National
Institutes of Health, Building 31, 31
Center Drive, Bethesda, MD 20892,
which was published in the Federal
Register on May 2, 2007, 72 FR 24319.
The notice is being amended to
change the open session start and end
times on June 14, 2007 to 1:15 p.m.—
4:20 p.m. and the end time on June 15,
2007 to 11:45 a.m. The meeting is
partially Closed to the public.
Dated: May 14, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–2495 Filed 5–18–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the provision
set forth in sections 552b(c)(4) and
552b(c)(6), Title 5 U.S.C., as amended.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; Clinical Trials
Review Committee.
Date: June 25, 2007.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Intercontinental Harbor Court, 550
Light Street, Baltimore, MD 21202.
Contact Person: Patricia A Haggerty, PhD,
Section Chief, Clinical Studies and Training
Scientific Review Group, Review Branch,
Division of Extramural Research Activities,
National Heart, Lung, and Blood Institute,
NIH, 6701 Rockledge Drive, Room 7194, MSC
7924, Bethesda, MD 20892, 301/435–0288,
haggertp@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: May 14, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–2488 Filed 5–18–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby give of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Mentored Scientist Award (K99).
Date: June 28–29, 2007.
Time: June 28, 2007, 12 p.m. to 10 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Plaza, 10 Thomas Circle
NW., Washington, DC 20005.
E:\FR\FM\21MYN1.SGM
21MYN1
]]>Agencies
[Federal Register Volume 72, Number 97 (Monday, May 21, 2007)]
[Notices]
[Page 28512]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-2495]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN
National Institutes of Health
National Cancer Institute; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Cancer Advisory Board, June 14, 2007, 2 p.m. to June 15, 2007, 12 p.m.,
National Institutes of Health, Building 31, 31 Center Drive, Bethesda,
MD 20892, which was published in the Federal Register on May 2, 2007,
72 FR 24319.
The notice is being amended to change the open session start and
end times on June 14, 2007 to 1:15 p.m.--4:20 p.m. and the end time on
June 15, 2007 to 11:45 a.m. The meeting is partially Closed to the
public.
Dated: May 14, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-2495 Filed 5-18-07; 8:45 am]
BILLING CODE 4140-01-M
